Business
SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical
About this update from Sellas Life Sciences Group, Inc.
[{"type":"text","content":"NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will present data relating to its highly selective CDK9 inhibitor, GFH009, during two poster presentations at the American Society of Hematology (ASH) Annual Meeting being held on December 10-13, 2022 in New Orleans, Louisiana. The meeting will also take place virtually. During the first poster presentation, SELLAS will share data related to GFH009’s mechanism of action associated anti-proliferative activity in various hematologic malignancies. The second poster presentation highlights preliminary safety and efficacy data from the first-in-human study of GFH009 in patients with relapsed / refractory hematologic malignancies. Additional presentation details can be found below: Title: “In Vitro and In Vivo Studies Support GFH009, a Selective CDK9 Inhibitor, As a Potential Treatment for Hematologic Cancers” Abstract #: 3477 Session Name: 802. Chemical Biology and Experimental Therapeutics: Poster II Date/Time: Sunday, December 11, 2022 at 6:00 PM CT Location: Ernest N. Morial Convention Center, Hall D Presenter: Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS Title: “First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies” Abstract #: 4263 Session Name: 626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III Date/Time: Monday, December 12, 2022 at 6:00 PM CT Location: Ernest N. Morial Convention Center, Hall D Presenter: Dr. Siyuan Le of GenFleet About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH0...